- Home
- INSI vs FENC Comparison
INSI vs FENC Comparison
Compare INSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- FENC
- Stock Information
- Founded
- INSI 1971
- FENC 1996
- Country
- INSI United States
- FENC United States
- Employees
- INSI N/A
- FENC N/A
- Industry
- INSI Investment Managers
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSI Finance
- FENC Health Care
- Exchange
- INSI Nasdaq
- FENC Nasdaq
- Market Cap
- INSI 173.3M
- FENC 156.9M
- IPO Year
- INSI N/A
- FENC 2001
- Fundamental
- Price
- INSI $16.23
- FENC $6.70
- Analyst Decision
- INSI
- FENC Strong Buy
- Analyst Count
- INSI 0
- FENC 2
- Target Price
- INSI N/A
- FENC $14.00
- AVG Volume (30 Days)
- INSI 22.0K
- FENC 58.2K
- Earning Date
- INSI 01-01-0001
- FENC 03-20-2025
- Dividend Yield
- INSI 4.90%
- FENC N/A
- EPS Growth
- INSI N/A
- FENC N/A
- EPS
- INSI N/A
- FENC N/A
- Revenue
- INSI N/A
- FENC $49,348,000.00
- Revenue This Year
- INSI N/A
- FENC $170.43
- Revenue Next Year
- INSI N/A
- FENC $6.70
- P/E Ratio
- INSI N/A
- FENC N/A
- Revenue Growth
- INSI N/A
- FENC 278.09
- 52 Week Low
- INSI $14.28
- FENC $3.96
- 52 Week High
- INSI $16.40
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- INSI 31.79
- FENC 67.46
- Support Level
- INSI $16.07
- FENC $6.30
- Resistance Level
- INSI $16.52
- FENC $6.76
- Average True Range (ATR)
- INSI 0.22
- FENC 0.28
- MACD
- INSI -0.06
- FENC 0.06
- Stochastic Oscillator
- INSI 13.56
- FENC 93.98
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.